The apolipoprotein E ε4 allele selectively increases the risk of frontotemporal lobar degeneration in males

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 2, 2006, Pages 154-158

  Srinivasan, R ^a   Davidson, Y ^a   Gibbons, L ^a   Payton, A ^a   Richardson, A M T ^b   Varma, A ^b   Julien, C ^b   Stopford, C ^b   Thompson, J ^b   Horan, M A ^a   Pendleton, N ^a   Pickering Brown, S M ^c   Neary, D ^b   Snowden, J S ^b   Mann, D M A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON4; DNA; TAU PROTEIN; UNCLASSIFIED DRUG; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; MAPT PROTEIN, HUMAN; NERVE PROTEIN;

ADULT; AGED; ARTICLE; BRAIN DEGENERATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; FRONTOTEMPORAL LOBAR DEGENERATION; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEX DIFFERENCE; TAU GENE; ALLELE; CEREBELLUM; DEMENTIA; FRONTAL LOBE; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; RISK;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CEREBELLUM; DEMENTIA; DISEASE SUSCEPTIBILITY; DNA MUTATIONAL ANALYSIS; FEMALE; FRONTAL LOBE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; RISK; SEX FACTORS; TAU PROTEINS;

EID: 32344434738     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2005.063966     Document Type: Article

References (37)

1. Corder EH, Sounders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
2. Czech C, Forstl H, Monning U. ApoE4 in clinically diagnosed Alzheimer's disease, frontal lobe degeneration and non-demented controls. Neurobiol Ageing 1994;15(suppl 1):S132.
3. Frisoni GB, Calabresi L, Geroldi C, et al. Apolipoprotein E ε4 allele in Alzheimer's disease and vascular dementia. Dementia 1994;5:240-2.
4. Farrer LA, Abraham CR, Volicer L, et al. Allele ε4 of apolipoprotein E shows a dose effect on age at onset of Pick disease. Exp Neurol 1995;136:162-70.
5. Schneider JA, Gearing M, Robbins RS, et al. Apolipoprotein E genotype in diverse neurodegenerative disorders. Ann Neurol 1995;38:131-5.
6. Helisalmi S, Linnaranta K, Lehtovirta M, et al. Apolipoprotein E polymorphism in patients with different neurodegenerative disorders. Neurosci Lett 1996;205:61-4.
7. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996;38:131-5.
8. Stevens M, van Duijn CM, de Knijff P, et al. Apolipoprotein E gene and sporadic frontal lobe dementia. Neurology 1997;48:1526-9.
9. Gustafson L, Abrahamson M, Grubb A, et al. Apolipoprotein E-genotyping in Alzheimer's disease and frontotemporal dementia. Dement Geriatr Cogn Disord 1997;8:1625-8.
10. Kalman J, Juhasz A, Majtenyi K, et al. Apolipoprotein E polymorphism in Pick's disease and in Huntington's disease. Neurobiol Ageing 2000;21:555-8.
11. Fabre SF, Forsell C, Viitanen M, et al. Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E ε4 frequency, but no tau gene mutations. Exp Neurol 2001;168:413-18.
12. Ingelson M, Fabre SF, Lilius L, et al. Increased risk for frontotemporal dementia through interaction between tau polymorphisms and apolipoprotein E epsilon4. NeuroReport 2001;12:905-9.
13. Rosso SM, van Swieten JC, Roks G, et al. Apolipoprotein E4 in the temporal variant of frontotemporal dementia. J Neurol Neurosurg Psychiatry 2002;72:820.
14. Minthon L, Hesse C, Sjogren M, et al. The Apolipoprotein E ε4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease. Neurosci Lett 1997;226:65-7.
15. Pickering-Brown SM, Siddons M, Mann DM, et al. Apolipoprotein E allelic frequencies in patients with lobar atrophy. Neurosci Lett 1995;188:205-7.
16. Pickering-Brown SM, Owen F, Snowden JS, et al. Apolipoprotein E E4 allele has no effect on age at onset or duration of disease in cases of frontotemporal dementia with Pick- or microvacuolar-type histology. Exp Neurol 2000;163:452-6.
17. Geschwind D, Karrim J, Nelson SF, et al. The apolipoprotein E epsilon4 allele is not a significant risk factor for frontotemporal dementia. Ann Neurol 1998;44:134-8.
18. Kowalska A, Asada T, Arima K, et al. Genetic analysis in patients with familial and sporadic frontotemporal dementia: two tau mutations in only familial cases and no association with Apolipoprotein ε4. Dement Geriatr Cogn Disord 2001;12:387-92.
19. Verpillat P, Camuzat A, Hannequin D, et al. Apoliporotein E gene in frontotemporal dementia: an association study and meta-analysis. Eur J Hum Genet 2002;10:399-405.
20. Riemenschneider M, Diehl J, Muller U, et al. Apolipoprotein E polymorphism in German patients with frontotemporal degeneration. J Neurol Neurosurg Psychiatry 2002;72:639-43.
21. Short RA, Graff-Radford NR, Adamson J, et al. Differences in tau and apolipoprotein E polymorphism frequencies in sporadic frontotemporal lobar degeneration syndromes. Arch Neurol 2002;59:611-15.
22. Binetti G, Nicosia F, Benussi L, et al. Prevalence of TAU mutations in an Italian clinical series of familial frontotemporal patients. Neurosci Lett 2003;338:85-7.
23. Nielsen AS, Ravid R, Kamphorst W, et al. Apolipoprotein E ε4 in an autopsy series of various dementing disorders. J Alzheimers Dis 2003;5:119-25.
24. Houlden H, Rizzu P, Stevens M, et al. Apolipoprotein E genotype does not affect age at onset of dementia in families with defined tau mutations. Neurosci Lett 1999;260:193-5.
25. Pickering-Brown SM, Richardson AMT, Snowden JS, et al. Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene. Brain 2002;125:732-51.
26. Lehmann DJ, Smith AD, Combrinck M, et al. Apolipoprotein E ε2 may be a risk factor for sporadic frontotemporal dementia. J Neurol Neurosurg Psychiatry 2000;69:404-5.
27. Brun A, Englund E, Gustafson L, et al. Clinical, neuropsychological and neuropathological criteria for fronto-temporal dementia. J Neurol Neurosurg Psychiatry 1994;57:416-18.
28. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-54.
29. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splice-site mutation in tau with inherited dementia FTDP-17. Nature 1998;393:702-5.
30. Pickering-Brown SM, Richardson AMT, Snowden JS, et al. Inherited frontotemporal dementia in 9 British families associated with intronic mutations in the tau gene. Brain 2002;125:732-51.
31. Pickering-Brown S, Baker M, Bird T, et al. Evidence of a founder effect in families with frontotemporal dementia that harbour the tau +16 splice mutation. Am J Med Genet Part B Neuropsychiatric Genetics 2004;125B:79-82.
32. Pendleton N, Payton A, van den Boogerd EH, et al. Apolipoprotein E genotype does not predict decline in intelligence in healthy older adults. Neurosci Lett 2002;324:74-6.
33. Wenham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158-9.
34. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 1998;278:1349-50.
35. Lambert JC, Coyle N, Lendon CL. The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease. J Med Genet 2004;41:104-12.
36. Corder EH, Sounders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele decreases risk of late onset Alzheimer's disease. Nat Genet 1994;7:180-4.
37. Talbot C, Lendon CL, Craddock N, et al. Protection against Alzheimer's disease with apoE ε2. Lancet 1994;343:1432-3.